Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 5/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 5/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 3/20 | 0.30 |
| ▸ | RAB9A | P51151 | 3/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18336164 | 0.88 | NPC1 (0.31) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18337002 | 0.87 | FABP4 (0.32) | BACE1FABP4FABP5ALDH1A1MAPT | |
| SCHEMBL18335983 | 0.87 | ALDH1A1 (0.36) | LMNAALDH1A1MAPTHSD17B10NPC1 | |
| SCHEMBL18336097 | 0.85 | FABP4 (0.33) | FABP4FABP5ALOX15 | |
| SCHEMBL18336393 | 0.84 | TNIK (0.38) | LMNABACE1FABP4FABP5ALDH1A1 | |
| SCHEMBL18336908 | 0.82 | STAT3 (0.37) | LMNAFABP4FABP5ALDH1A1NPC1 | |
| SCHEMBL18336876 | 0.78 | IRAK4 (0.39) | FABP4FABP5ALDH1A1NPC1RAB9A | |
| SCHEMBL18337144 | 0.77 | ALDH1A1 (0.33) | LMNAALDH1A1MAPTHSD17B10NPC1 | |
| SCHEMBL6119983 | 0.76 | GAA (0.39) | BACE1MAPTHSD17B10NPC1RAB9A | |
| SCHEMBL18336211 | 0.76 | NPC1 (0.38) | HSP90AB1LMNAALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3683222-B1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-3683222-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-04 | — | — | US | disclosed |
| EP-3135674-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | CBR3, CBR1, CYCS | HSP90AB1 4699/4885LMNA 4127/4885BACE1 3605/4885 |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | CBR3, CBR1, CYCS | HSP90AB1 4724/4885LMNA 3999/4885BACE1 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.